Logo image
CD8+ T-cell Activation in HIV-1-Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy
Journal article   Open access   Peer reviewed

CD8+ T-cell Activation in HIV-1-Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy

Babafemi Taiwo, Peter W. Hunt, Rajesh T. Gandhi, Andrew Ellingson, Matthew McKenna, Jeffrey M. Jacobson, Barbara Gripshover and Ronald J. Bosch
Journal of acquired immune deficiency syndromes (1999), v 63(1), pp 101-104
01 May 2013
PMID: 23392463
url
https://journals.lww.com/jaids/fulltext/2013/05010/cd8__t_cell_activation_in_hiv_1_infected_patients.14.aspxView
Accepted (AM)Open Access (License Unspecified) Open

Abstract

activation blip CD8 immune low-level viremia
Transient low-level viremia of 50–400 HIV RNA copies/mL (TLLV) is common during antiretroviral therapy, but its pathogenesis, consequences and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4+ T-cell reconstitution. Using CD38/HLA-DR expression on CD8+ T-cells measured in two large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8+ T-cell activation, and that higher CD8+ T-cell activation during viral suppression <50 copies/mL is associated with a modest increase in the risk of a subsequent TLLV.

Metrics

5 Record Views
25 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Immunology
Infectious Diseases
Logo image